June 14, 2014 successful Phase III study results were shared from their melanoma trial. This comprehensive trial involved Cobimetinib and Zelboraf for treating patients with advanced cases of melanoma. All 495 patients had specific mutations of the BRAF gene and many were considered to have unresectable cases of this deadly skin cancer. The surprise came when they found these two drugs led to a longer progression free survival for patients in comparison to their treatment with Zelboraf…
A Genmab-sponsored study touts preclinical evidence that one of its targeted antibody-drug conjugates can be effective against a specific type of melanoma where existing treatment is failing, pointing to a potential new triple combination strategy. The BRAF gene is a well-studied pathway in melanoma, as a mutation in it causes
Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents .
The Swedish Society for Orthomolecular Medicine introduced Dr. Suzanne Humphries to lecture on the practical use of Vitamin C in Stockholm, Sweden.
What does LCH do? 78% have bone lesions, the most common area 50% have skin lesions 30% have lymph node involvement 20-50% have liver involvement • looks like primary sclerosing cholangitis & can be misdiagnosed as such • 75% need transplant -10% have Neurodegeneration -2% have lung involvement • looks like pulmonary fibrosis 20-30% have recurrences (relapse) 50-60% have the BRAF gene mutation • suspected there are additional (as yet unidentified) mutations responsible for the remainder
The New York Times is publishing a series on cancer research and a miracle drug for melanoma. These pics are before and after scans of a melanoma patient only 15 days after taking – a…
*** how to diagnose rectal cancer *** Despite being diagnosed with chemotherapy-resistant colorectal cancer three years ago, Tim Givens is not only alive; he’s also in remission, thanks to a Phase I clinical trial.